Bimiralisib Uses, Dosage, Side Effects and more
Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).
| Attribute | Details |
|---|---|
| Trade Name | Bimiralisib |
| Generic | Bimiralisib |
| Bimiralisib Other Names | Bimiralisib |
| Type | |
| Formula | C17H20F3N7O2 |
| Weight | Average: 411.389 Monoisotopic: 411.163057401 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
